CA3127928A1 - Methods of treating multiple myeloma - Google Patents
Methods of treating multiple myeloma Download PDFInfo
- Publication number
- CA3127928A1 CA3127928A1 CA3127928A CA3127928A CA3127928A1 CA 3127928 A1 CA3127928 A1 CA 3127928A1 CA 3127928 A CA3127928 A CA 3127928A CA 3127928 A CA3127928 A CA 3127928A CA 3127928 A1 CA3127928 A1 CA 3127928A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- individual
- dexamethasone
- pomalidomide
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797876P | 2019-01-28 | 2019-01-28 | |
| US62/797,876 | 2019-01-28 | ||
| US201962847826P | 2019-05-14 | 2019-05-14 | |
| US62/847,826 | 2019-05-14 | ||
| US201962861954P | 2019-06-14 | 2019-06-14 | |
| US62/861,954 | 2019-06-14 | ||
| US201962899094P | 2019-09-11 | 2019-09-11 | |
| US62/899,094 | 2019-09-11 | ||
| US201962931014P | 2019-11-05 | 2019-11-05 | |
| US62/931,014 | 2019-11-05 | ||
| EP19306554 | 2019-12-03 | ||
| EP19306554.7 | 2019-12-03 | ||
| US201962943716P | 2019-12-04 | 2019-12-04 | |
| US62/943,716 | 2019-12-04 | ||
| PCT/US2020/015455 WO2020160020A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3127928A1 true CA3127928A1 (en) | 2020-08-06 |
Family
ID=69646031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3127928A Pending CA3127928A1 (en) | 2019-01-28 | 2020-01-28 | Methods of treating multiple myeloma |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11939390B2 (enExample) |
| EP (2) | EP4588484A3 (enExample) |
| JP (2) | JP7712206B2 (enExample) |
| KR (1) | KR20210120048A (enExample) |
| CN (2) | CN120754030A (enExample) |
| AU (1) | AU2020215692A1 (enExample) |
| BR (1) | BR112021014699A2 (enExample) |
| CA (1) | CA3127928A1 (enExample) |
| CO (1) | CO2021011034A2 (enExample) |
| IL (2) | IL321343A (enExample) |
| MA (1) | MA54860A (enExample) |
| MX (1) | MX2021009079A (enExample) |
| SG (1) | SG11202108029XA (enExample) |
| TW (1) | TW202535952A (enExample) |
| WO (1) | WO2020160020A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2960282C (en) | 2014-09-12 | 2025-09-09 | The Regents Of The University Of California | Human anti-CD46 macropinosome-forming antibodies and target anti-cancer therapeutic agents |
| WO2020160020A1 (en) | 2019-01-28 | 2020-08-06 | Sanofi | Methods of treating multiple myeloma |
| MX2021013910A (es) * | 2019-05-14 | 2022-03-11 | Sanofi Sa | Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple. |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| AU2020397170A1 (en) * | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| IL300528A (en) * | 2020-08-07 | 2023-04-01 | Fortis Therapeutics Inc | Immune conjugates targeting cd46 and methods of using them |
| US20220135696A1 (en) * | 2020-11-03 | 2022-05-05 | Sanofi-Aventis U.S. Llc | Use of isatuximab for the treatment of multiple myeloma |
| CN114219787B (zh) * | 2021-12-17 | 2024-08-06 | 三峡大学 | 一种初诊多发性骨髓瘤预后分期系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ586780A (en) * | 2005-03-23 | 2012-02-24 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EA029085B1 (ru) * | 2012-08-09 | 2018-02-28 | Селджин Корпорейшн | Способ лечения иммуноопосредуемых и воспалительных заболеваний с помощью 3-[4-(4-морфолин-4-илметилбензилокси)-1-оксо-1,3-дигидроизоиндол-2-ил]пиперидин-2,6-диона |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| PT3294769T (pt) * | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma múltiplo (mm) |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
| PE20181323A1 (es) * | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US20180153989A1 (en) * | 2016-12-02 | 2018-06-07 | Rubius Therapeutics, Inc. | Compositions and methods related to cell systems for penetrating solid tumors |
| WO2019012328A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Pharma | ANTICANCER POLY THERAPY |
| WO2020160020A1 (en) | 2019-01-28 | 2020-08-06 | Sanofi | Methods of treating multiple myeloma |
-
2020
- 2020-01-28 WO PCT/US2020/015455 patent/WO2020160020A1/en not_active Ceased
- 2020-01-28 MX MX2021009079A patent/MX2021009079A/es unknown
- 2020-01-28 IL IL321343A patent/IL321343A/en unknown
- 2020-01-28 KR KR1020217027098A patent/KR20210120048A/ko active Pending
- 2020-01-28 SG SG11202108029XA patent/SG11202108029XA/en unknown
- 2020-01-28 CN CN202510783436.0A patent/CN120754030A/zh active Pending
- 2020-01-28 JP JP2021543372A patent/JP7712206B2/ja active Active
- 2020-01-28 EP EP25172506.5A patent/EP4588484A3/en active Pending
- 2020-01-28 MA MA054860A patent/MA54860A/fr unknown
- 2020-01-28 AU AU2020215692A patent/AU2020215692A1/en active Pending
- 2020-01-28 CA CA3127928A patent/CA3127928A1/en active Pending
- 2020-01-28 BR BR112021014699A patent/BR112021014699A2/pt unknown
- 2020-01-28 US US16/775,025 patent/US11939390B2/en active Active
- 2020-01-28 CN CN202080024773.7A patent/CN114026121A/zh active Pending
- 2020-01-28 EP EP20706606.9A patent/EP3917961A1/en active Pending
- 2020-01-30 TW TW114114347A patent/TW202535952A/zh unknown
-
2021
- 2021-07-25 IL IL285110A patent/IL285110B2/en unknown
- 2021-08-23 CO CONC2021/0011034A patent/CO2021011034A2/es unknown
-
2024
- 2024-02-16 US US18/443,878 patent/US20240190984A1/en active Pending
-
2025
- 2025-07-09 JP JP2025115594A patent/JP2025148430A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3917961A1 (en) | 2021-12-08 |
| US11939390B2 (en) | 2024-03-26 |
| AU2020215692A1 (en) | 2021-09-16 |
| US20240190984A1 (en) | 2024-06-13 |
| IL285110B2 (en) | 2025-11-01 |
| CN120754030A (zh) | 2025-10-10 |
| IL321343A (en) | 2025-08-01 |
| TW202043283A (zh) | 2020-12-01 |
| US20200239589A1 (en) | 2020-07-30 |
| BR112021014699A2 (pt) | 2021-11-23 |
| IL285110B1 (en) | 2025-07-01 |
| JP2025148430A (ja) | 2025-10-07 |
| EP4588484A2 (en) | 2025-07-23 |
| CN114026121A (zh) | 2022-02-08 |
| IL285110A (en) | 2021-09-30 |
| SG11202108029XA (en) | 2021-08-30 |
| JP2022518060A (ja) | 2022-03-11 |
| WO2020160020A1 (en) | 2020-08-06 |
| CO2021011034A2 (es) | 2021-09-09 |
| EP4588484A3 (en) | 2025-10-15 |
| TW202535952A (zh) | 2025-09-16 |
| MA54860A (fr) | 2022-05-04 |
| MX2021009079A (es) | 2022-02-10 |
| KR20210120048A (ko) | 2021-10-06 |
| JP7712206B2 (ja) | 2025-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240190984A1 (en) | Methods of treating multiple myeloma | |
| US20190309071A1 (en) | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| JP2025166108A (ja) | 抗cd38抗体を投与して多発性骨髄腫を処置する方法 | |
| JP2025138745A (ja) | 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 | |
| RU2838203C2 (ru) | Способы лечения множественной миеломы | |
| CA3048198A1 (en) | Methods of treating multiple myeloma | |
| TWI904081B (zh) | 治療多發性骨髓瘤的方法 | |
| JP2021505545A (ja) | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 | |
| US20250177519A1 (en) | Use of isatuximab in combination with other agents for the treatment of multiple myeloma | |
| TW202541838A (zh) | 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240126 |